This trial tests the safety and effectiveness of a new anti-VEGF injection compared to a standard one.
1 Primary · 1 Secondary · Reporting Duration: Demonstrate a reduction in mean 1-hr post-injection pain scores
2 Treatment Groups
1 of 2
1 of 2
240 Total Participants · 2 Treatment Groups
Primary Treatment: IRX-101 · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the Federal Drug Administration sanctioned the use of IRX-101?
"IRX-101 is perceived to be highly safe, as evidenced by its 3 score on the Power scale. This reflects multiple rounds of data that validate efficacy and safety within Phase 3 trials." - Anonymous Online Contributor
Are there any opportunities to take part in this clinical experiment currently?
"Affirmative. Documentation available on clinicaltrials.gov reveals that this study, which was advertised since February 22nd 2023, is open to enrollment. The trial necessitates the recruitment of 240 volunteers from a single site." - Anonymous Online Contributor
How many individuals are being selected to partake in this research?
"Affirmative. According to the information on clinicaltrials.gov, this medical experiment began recruiting patients on February 22nd 2023 and was recently updated March 1st 2023. It is currently looking for 240 people from a single research site." - Anonymous Online Contributor